Jack Wallace
Stock Analyst at Guggenheim
(3.14)
# 1,138
Out of 5,147 analysts
18
Total ratings
57.89%
Success rate
273.86%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $182.01 | +36.81% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $14.52 | +17.08% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $1.62 | +764.20% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $178.81 | +23.04% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $12.33 | +224.41% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $5.70 | +1,654.39% | 1 | Mar 15, 2023 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $182.01
Upside: +36.81%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $14.52
Upside: +17.08%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $1.62
Upside: +764.20%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $178.81
Upside: +23.04%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $12.33
Upside: +224.41%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $5.70
Upside: +1,654.39%